Adenoviral vectors--how to use them in cancer gene therapy? (Q36419822)

14 August 2017

1 reference

title

Adenoviral vectors--how to use them in cancer gene therapy? (English)

1 reference

14 August 2017

0 references

1 reference

1 reference

Dragomira Majhen

1

1 reference

PubMed ID

16533542

14 August 2017

Andreja Ambriović-Ristov

series ordinal

2

1 reference

14 August 2017

14 March 2006

1 reference

14 August 2017

1 reference

14 August 2017

119

1 reference

14 August 2017

2

1 reference

14 August 2017

121-133

1 reference

Differential suppression of human cervical cancer cell growth by adenovirus delivery of p53 in vitro: arrest phase of cell cycle is dependent on cell line

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Replicative adenoviruses for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Efficacy of replication-defective adenovirus-vectored vaccines: protection following intramuscular injection is linked to promoter efficiency in muscle representative cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Shortening adenovirus type 5 fiber shaft decreases the efficiency of postbinding steps in CAR-expressing and nonexpressing cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

The coxsackie B virus and adenovirus receptor resides in a distinct membrane microdomain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Targeted adenoviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Adenovirus promoters and E1A transactivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

CD13/APN is activated by angiogenic signals and is essential for capillary tube formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Genetically modified adenovirus vector containing an RGD peptide in the HI loop of the fiber knob improves gene transfer to nonhuman primate isolated pancreatic islets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Complex mosaicism is a novel approach to infectivity enhancement of adenovirus type 5-based vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Polylysine modification of adenoviral fiber protein enhances muscle cell transduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

A genetically retargeted adenoviral vector enhances viral transduction in esophageal carcinoma cell lines and primary cultured esophageal resection specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Transcriptional targeting for ovarian cancer gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Targeted gene delivery by tropism-modified adenoviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

A system for the propagation of adenoviral vectors with genetically modified receptor specificities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Transductional targeting of adenoviral cancer gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Expression of the coxsackie and adenovirus receptor in human astrocytic tumors and xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Transcription-controlled gene therapy against tumor angiogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Cancer vaccines and immunotherapies: emerging perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Adenovirus stripping: a versatile method to generate adenovirus vectors with new cell target specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Adenovirus-mediated tissue-specific cytosine deaminase gene therapy for human hepatocellular carcinoma with different AFP expression levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Enhancement of the adenoviral sensitivity of human ovarian cancer cells by transient expression of coxsackievirus and adenovirus receptor (CAR).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Genetic targeting of adenoviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Latest development in viral vectors for gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

7 January 2021

Adenovirus endocytosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Transcriptional targeting of RGD fiber-mutant adenovirus vectors can improve the safety of suicide gene therapy for murine melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Probing the structural and molecular diversity of tumor vasculature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Phage display of adenovirus type 5 fiber knob as a tool for specific ligand selection and validation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Retargeting the coxsackievirus and adenovirus receptor to the apical surface of polarized epithelial cells reveals the glycocalyx as a barrier to adenovirus-mediated gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Ionizing radiation-induced adenovirus infection is mediated by Dynamin 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Transcriptional Targeting in Cancer Gene Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Functional analysis of adenovirus protein IX identifies domains involved in capsid stability, transcriptional activity, and nuclear reorganization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

7 January 2021

Drug targeting to specific vascular sites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Adenovirus types 11p and 35p show high binding efficiencies for committed hematopoietic cell lines and are infective to these cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Efficient infection of tumor endothelial cells by a capsid-modified adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Adenovirus-mediated suicide SCLC gene therapy using the increased activity of the hTERT promoter by the MMRE and SV40 enhancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Gene transfer to carcinoma of the breast with fiber-modified adenoviral vectors in a tissue slice model system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

New triple-helical model for the shaft of the adenovirus fibre.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Tumor necrosis factor-alpha induces Bax-Bak interaction and apoptosis, which is inhibited by adenovirus E1B 19K

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Molecular regulation and biological function of adenovirus early genes: the E4 ORFs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Gene-based strategies for the immunotherapy of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Recombinant adenovirus vectors with knobless fibers for targeted gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Cytokine-mediated downregulation of coxsackievirus-adenovirus receptor in endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Retargeting of adenoviral vector using basic fibroblast growth factor ligand for malignant glioma gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Gene targets of antisense therapies in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Why did p53 gene therapy fail in ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Requirement of the adenovirus IVa2 protein for virus assembly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

7 January 2021

Group D adenoviruses infect primary central nervous system cells more efficiently than those from group C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

7 January 2021

An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

7 January 2021

Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

7 January 2021

Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

7 January 2021

A replication-incompetent adenovirus vector with the preterminal protein gene deleted efficiently transduces mouse ears

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

7 January 2021

Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

7 January 2021

Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

7 January 2021

Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2006.02.001

7 January 2021

10.1016/J.VIRUSRES.2006.02.001

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16533542